Inovio Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Inovio Pharmaceuticals wird ein Gewinn- und Umsatzwachstum von 26.2% bzw. 74.4% pro Jahr prognostiziert, während der Gewinn pro Aktie um 33.7% pro Jahr wachsen soll.

Wichtige Informationen

26.2%

Wachstumsrate der Gewinne

33.7%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	74.4%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	18 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Here's Why We're Watching Inovio Pharmaceuticals' (NASDAQ:INO) Cash Burn Situation

Aug 11

Some Analysts Just Cut Their Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Estimates

May 15

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Just Reported And Analysts Have Been Cutting Their Estimates

May 13

Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?

Oct 23

Inovio reports positive phase 1/2 results for recurrent respiratory papillomatosis drug

Oct 13

Inovio Pharmaceuticals: Long On Promise, Short On Results

Sep 27

Inovio Pharmaceuticals GAAP EPS of -$0.46 misses by $0.15, revenue of $0.78M beats by $0.26M

Aug 09

Inovio Pharmaceuticals: Forget The COVID Pump, And Keep Your Eye On The Oncology Side

Nov 18

Rock star Growth Puts Inovio Pharmaceuticals (NASDAQ:INO) In A Position To Use Debt

Sep 24

Inovio: Simply Cannot Be Ignored

Sep 03

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:INO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	27	-98	-78	N/A	4
12/31/2025	3	-113	-191	N/A	6
12/31/2024	0	-113	-120	N/A	5
9/30/2024	0	-113	-111	-111	N/A
6/30/2024	1	-122	-113	-112	N/A
3/31/2024	1	-125	-117	-116	N/A
12/31/2023	1	-135	-125	-124	N/A
9/30/2023	1	-165	-135	-134	N/A
6/30/2023	10	-168	-173	-173	N/A
3/31/2023	10	-241	-192	-191	N/A
12/31/2022	10	-280	-217	-216	N/A
9/30/2022	11	-332	-219	-218	N/A
6/30/2022	2	-355	-198	-197	N/A
3/31/2022	2	-328	-226	-225	N/A
12/31/2021	2	-304	-217	-216	N/A
9/30/2021	7	-221	-231	-229	N/A
6/30/2021	6	-142	-258	-257	N/A
3/31/2021	6	-188	-207	-205	N/A
12/31/2020	7	-166	-179	-178	N/A
9/30/2020	2	-180	-141	-140	N/A
6/30/2020	3	-222	-94	-94	N/A
3/31/2020	3	-123	-91	-91	N/A
12/31/2019	4	-119	-99	-98	N/A
9/30/2019	6	-115	-103	-101	N/A
6/30/2019	7	-117	-100	-98	N/A
3/31/2019	32	-94	-95	-93	N/A
12/31/2018	30	-97	-76	-74	N/A
9/30/2018	37	-86	-72	-70	N/A
6/30/2018	37	-95	N/A	-63	N/A
3/31/2018	33	-97	N/A	-61	N/A
12/31/2017	42	-88	N/A	-63	N/A
9/30/2017	42	-93	N/A	-64	N/A
6/30/2017	52	-80	N/A	-65	N/A
3/31/2017	38	-89	N/A	-62	N/A
12/31/2016	35	-74	N/A	-63	N/A
9/30/2016	33	-65	N/A	-54	N/A
6/30/2016	44	-39	N/A	-20	N/A
3/31/2016	44	-27	N/A	-16	N/A
12/31/2015	41	-29	N/A	-12	N/A
9/30/2015	37	-19	N/A	-14	N/A
6/30/2015	15	-31	N/A	-37	N/A
3/31/2015	13	-36	N/A	-36	N/A
12/31/2014	10	-36	N/A	-30	N/A
9/30/2014	10	-44	N/A	-21	N/A
6/30/2014	17	-68	N/A	-19	N/A
3/31/2014	14	-68	N/A	-16	N/A
12/31/2013	13	-66	N/A	-15	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: INO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: INO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: INO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: INODie Einnahmen des Unternehmens (74.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: INODie Einnahmen des Unternehmens (74.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von INO in 3 Jahren voraussichtlich hoch sein wird

Inovio Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 25% to US$11.83

Consensus revenue estimates fall by 16%

Price target decreased by 11% to US$16.75

Consensus revenue estimates fall by 31%

Price target decreased by 11% to US$16.88

Consensus EPS estimates upgraded to US$4.86 loss

Recent updates

Price target decreased by 25% to US$11.83

New major risk - Financial position

Inovio Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Consensus revenue estimates fall by 16%

Inovio Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $60 million.

Price target decreased by 11% to US$16.75

Here's Why We're Watching Inovio Pharmaceuticals' (NASDAQ:INO) Cash Burn Situation

New minor risk - Profitability

New major risk - Financial position

Inovio Pharmaceuticals, Inc. Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107

Inovio Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 08, 2024

INOVIO Announces INO-3107 Receives the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway

INOVIO Appointsof Steven Egge as Chief Commercial Officer

Consensus revenue estimates fall by 31%

First quarter 2024 earnings released: US$1.31 loss per share (vs US$1.89 loss in 1Q 2023)

Inovio Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 13, 2024

Inovio Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $35.937522 million.

Inovio Pharmaceuticals, Inc., Annual General Meeting, May 21, 2024

New major risk - Share price stability

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 11% to US$16.88

Inovio Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 06, 2024

Consensus EPS estimates upgraded to US$4.86 loss

Price target increased by 50% to US$2.00

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Inovio Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Inovio Pharmaceuticals, Inc. Receives FDA Feedback That Data from Completed Phase 1/2 Trial of INO-3107

New minor risk - Market cap size

Consensus revenue estimates decrease by 49%, EPS upgraded

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Inovio Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New major risk - Share price stability

Inovio Pharmaceuticals, Inc.(NasdaqGS:INO) dropped from Russell 2000 Value Index

Consensus revenue estimates fall by 16%

Some Analysts Just Cut Their Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Estimates

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Just Reported And Analysts Have Been Cutting Their Estimates

First quarter 2023 earnings: EPS and revenues miss analyst expectations

INOVIO Presents New Data from A Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Price target decreased by 40% to US$1.40

Inovio Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Inovio Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 01, 2023

Inovio Reports Positive Phase 1B Results for INO-4201 as an Ebola Booster for rVSV-Zebov (Ervebo®)

Inovio Pharmaceuticals, Inc. Announces Strategic Reorganization and 11% Reduction of Full-Time Employees

Consensus forecasts updated

Price target decreased to US$2.25

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

INOVIO Provides Update on COVID-19 Heterologous Booster Vaccine Candidate, INO-4800

Inovio Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Is Inovio Pharmaceuticals (NASDAQ:INO) Using Debt Sensibly?

INOVIO Reports Positive Interim Phase 1/2 Results for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

Inovio reports positive phase 1/2 results for recurrent respiratory papillomatosis drug

Inovio Pharmaceuticals: Long On Promise, Short On Results

Board Member exercised options and sold US$5.9k worth of stock

Consensus revenue estimates fall by 43%

Board Member exercised options and sold US$5.9k worth of stock

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Inovio Pharmaceuticals GAAP EPS of -$0.46 misses by $0.15, revenue of $0.78M beats by $0.26M

Inovio Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Consensus forecasts updated

Inovio: After All These Years

INOVIO Announces Survival Results for INO-5401 + INO-9012 in Combination with Libtayo(R) (cemiplimab) in Patients with Newly Diagnosed GBM

Consensus forecasts updated

INOVIO Announces Board Changes

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$9.57

No longer forecast to breakeven

Inovio: Long-Term Biotech To Own With Several Catalysts Expected In 2022

Board Member exercised options and sold US$13k worth of stock